Researchers have developed a new non-invasive test to detect endometrial cancer using cervical cells collected during a routine Pap smear. The method analyzes DNA methylation changes and focuses on three gene markers—ZNF626, GRIA4, and SPDYA. The test, called MATS, showed strong performance in validation studies, achieving about 95% sensitivity and 90% specificity. It also detected more […]
Researchers have discovered that advanced tumors can manipulate the metabolism of erythroid progenitor cells (EPCs), a type of immature red blood cell, to suppress the body’s immune response. In many cancer patients, tumors stimulate the production of these cells outside the bone marrow, mainly in the spleen. Some EPCs enter the tumor microenvironment where they
Researchers have discovered a new survival strategy used by pancreatic cancer cells: sharing protein-making machinery through tiny cellular bridges called tunneling nanotubes (TNTs). Pancreatic ductal adenocarcinoma (PDAC) cells use these tubes to exchange messenger RNA, ribosomal components, and even fully assembled ribosomes, effectively supplying each other with the tools needed to make proteins and survive.
Pancreatic Cancer Cells Survive Chemotherapy by Sharing Protein Factories Read More »
Researchers have developed a new genome-editing tool designed to target pancreatic ductal adenocarcinoma (PDAC), one of the deadliest cancers. The team engineered an improved cytosine base editor using a human protein called APOBEC3F. By combining artificial intelligence–based protein modeling with structure-guided engineering, they created optimized versions that improve editing efficiency and accuracy while reducing unwanted
New Genome Editing Tool Targets KRAS and MYC in Pancreatic Cancer Read More »
A study reports a potential new treatment strategy for nasopharyngeal carcinoma (NPC) by targeting a protein complex known as CRL4–DTL. Researchers used bioinformatics and laboratory experiments to identify DTL as a key gene that is highly expressed in NPC tumors. High levels of DTL were linked to more advanced disease and poorer patient outcomes, suggesting
A study reports long-term results from the CCTG PA.7 phase II trial testing whether adding immunotherapy to chemotherapy improves outcomes for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). The trial evaluated the combination of durvalumab and tremelimumab with standard chemotherapy (gemcitabine and nab-paclitaxel). Overall, the addition of immunotherapy did not significantly improve survival in the
Antibody–drug conjugates (ADCs) are emerging as a promising targeted treatment for pancreatic ductal adenocarcinoma (PDAC), one of the deadliest cancers with a five-year survival rate of about 10%. PDAC is difficult to treat because tumors are surrounded by dense fibrotic tissue that blocks drug delivery. The disease is also highly diverse at the molecular level
New Antibody–Drug Conjugates Show Promise for Treating Pancreatic Cancer Read More »
A phase 2 clinical trial has reported encouraging results for zovegalisib (RLY-2608), a new targeted drug for advanced breast cancer. The study involved patients with HR-positive, HER2-negative metastatic breast cancer carrying PIK3CA mutations who had already progressed after standard treatments such as CDK4/6 inhibitors. Researchers found an overall response rate of 38.7%, while patients with
Phase 2 Trial Shows Promising Results for Zovegalisib in PIK3CA-Mutant Breast Cancer Read More »
Researchers have discovered that γδ T cells play a key role in shaping the immune environment of lung adenocarcinoma. In mouse models, these cells were found to accumulate in tumor-bearing lungs, recruited from the bloodstream rather than multiplying on-site. Once in the tumor, they showed reduced activation and produced fewer anti-tumor molecules, while clustering near
Study Finds γδ T Cells Drive Profibrotic Macrophages in Lung Adenocarcinoma Read More »
A population-based study using the Surveillance, Epidemiology, and End Results Program (SEER) database analyzed early mortality in patients with Angioimmunoblastic Tcell lymphoma (AITL) between 2000 and 2021. Researchers defined early mortality as death within 24 months of diagnosis. The results showed that AITL has a high risk of early death, with mortality reaching 38.5% within the first year and